Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
NCT02009384 · University of Louisville · PHASE2 · terminated · last registry update 2021-10-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low enrollment r/t requirement of prior treatment with denileukin diftitox” | – | Registry record, University of Louisville |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CTLA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-28Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Cisplatin (NCT02998528)
- 2022-09-27Results posted on the registry: Dana-Farber Cancer Institute, Nivolumab + Ipilimumab (NCT03789110)
- 2022-04-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Cabozantinib (NCT03141177)
- 2022-04-25Results posted on the registry: Toni Choueiri, MD, Ipilimumab + Nivolumab (NCT03203473)
- 2022-03-22Results posted on the registry: Brown University, Ipilumumab + Nivolumab (NCT02656706)
- 2022-03-02Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT03143153)
- 2022-01-11Results posted on the registry: SWOG Cancer Research Network, Ipilimumab + Nivolumab (NCT02785952)
- 2021-12-03Phase 3 first posted: Ono Pharmaceutical Co., Ltd., ONO-4538 + Ipilimumab (NCT05144854)
- 2021-12-01Results posted on the registry: CytomX Therapeutics, CX-072 + Ipilimumab (NCT03993379)
- 2021-09-14Results posted on the registry: Immunocore Ltd, IMCgp100 + Dacarbazine (NCT03070392)
- 2021-06-18Phase 3 first posted: National Cancer Institute (NCI), Ipilimumab + Nivolumab (NCT04929041)
- 2021-05-27Results posted on the registry: National Cancer Institute (NCI), Ipilimumab + Recombinant Interferon Alfa-2b (NCT01274338)
- 2021-05-14Phase 3 first posted: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT04887870)
- 2021-03-22Results posted on the registry: Bristol-Myers Squibb, BMS-936558 (MDX1106-04) + Ipilimumab (NCT01024231)
- 2021-02-03Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT04736706)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision